October 2020 // Funding

Updated: Nov 6, 2020

Synendos Therapeutics has been awarded of an Innosuisse Innovation Grant in collaboration with the group of Prof. J. Gertsch at the University of Bern. The funded project aims to characterize the new drug target of SERIs and to perform other explorative activities on biology and pharmacology of SERIs. The grant (ca. CHF 1m) has a duration of 3 years.



Recent Posts

See All

April 2021 // Investment

Synendos Series A Extension Synendos Therapeutics is thrilled to announce an extension to the Series A financing with the addition of Ysios Capital to its syndicate of European investors. Ysios Capita